<- Go Home

4basebio PLC

4basebio PLC engages in the research, development, manufacturing, and commercialization of synthetic DNA and RNA products, and targeted non-viral vector solutions in the United States, Europe, and internationally. The company offers AVV and Lentivirus manufacturing services for use in gene therapies and vaccines. It also offers access to its targeted non-viral delivery platform, Hermes. The company was formerly known as 4basebio UK Societas and changed its name to 4basebio PLC in July 2021. 4basebio PLC was founded in 2008 and is based in Cambridge, the United Kingdom.

Market Cap

GBP 144.1M

Volume

2.9K

Cash and Equivalents

GBP 2.7M

EBITDA

-GBP 9.6M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

GBP 415.0K

Profit Margin

69.63%

52 Week High

GBP 18.20

52 Week Low

GBP 10.20

Dividend

N/A

Price / Book Value

-27.61

Price / Earnings

-14.31

Price / Tangible Book Value

-23.87

Enterprise Value

GBP 156.8M

Enterprise Value / EBITDA

-16.51

Operating Income

-GBP 10.2M

Return on Equity

1088.88%

Return on Assets

-54.30

Cash and Short Term Investments

GBP 2.7M

Debt

GBP 15.5M

Equity

-GBP 5.2M

Revenue

GBP 596.0K

Unlevered FCF

-GBP 6.7M

Sector

Biotechnology

Category

N/A

Hedge Funds that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Yellowbrick Portfolios that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Company Stock Pitches